Veteran life-sciences executive and investor focused on biotech strategy, clinical-stage assets and translational research commercialization. Neil Greenspan brings operating and advisory experience across therapeutics development, partnering and capital formation, often supporting seed-to-growth equity rounds and licensing transactions. Background blends scientific leadership with board and advisory roles, informing go-to-market assessments, pipeline valuation and risk-adjusted investment theses. Active in deal sourcing, due diligence and cross-disciplinary management of R&D portfolios, with experience working alongside institutional investors and corporate partners to advance clinical programs. Market-relevant strengths include technical vetting of targets, structuring collaborative alliances and advising on exit pathways for early-stage life-science ventures.
Veteran life-sciences executive and investor focused on biotech strategy, clinical-stage assets and translational research commercialization. Neil Greenspan brings operating and advisory experience across therapeutics development, partnering and capital formation, often supporting seed-to-growth equity rounds and licensing transactions. Background blends scientific leadership with board and advisory roles, informing go-to-market assessments, pipeline valuation and risk-adjusted investment theses. Active in deal sourcing, due diligence and cross-disciplinary management of R&D portfolios, with experience working alongside institutional investors and corporate partners to advance clinical programs. Market-relevant strengths include technical vetting of targets, structuring collaborative alliances and advising on exit pathways for early-stage life-science ventures.
Brings a science-led, active-investor approach to early and clinical-stage biotech, prioritizing translational assets with clear de-risking pathways and demonstrable mechanistic validation. Capital allocation favors seed-to-growth equity and structured licensing where technical due diligence, milestone-driven financing and partner syndication reduce binary clinical risk. Investment horizon is medium-to-long, focused on value creation through catalytic data readouts, alliance formation and disciplined portfolio construction. Decisions emphasize deep technical vetting, pragmatic go‑to‑market planning and exit strategies aligned with strategic acquirers and public markets.
Brings a science-led, active-investor approach to early and clinical-stage biotech, prioritizing translational assets with clear de-risking pathways and demonstrable mechanistic validation. Capital allocation favors seed-to-growth equity and structured licensing where technical due diligence, milestone-driven financing and partner syndication reduce binary clinical risk. Investment horizon is medium-to-long, focused on value creation through catalytic data readouts, alliance formation and disciplined portfolio construction. Decisions emphasize deep technical vetting, pragmatic go‑to‑market planning and exit strategies aligned with strategic acquirers and public markets.
| Trades 2178 | Longs Won 1557/2178 71% | Profit Factor 8.34 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $549,569.7 |
| Average Win $139,664.47 | Best Trade (Oct 16) $9.7M | Sharpe Ratio -49.48 |
| Average Loss -$42,008.88 | Worst Trade (Oct 16) -$4.71M | Z-Score 17.02 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 3w 1d | Expectancy $87,865.05 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 11,628 | 10,465 | 9,302 | 8,140 | 6,977 | 5,814 | 4,651 | 3,488 | 2,326 | 1,163 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 19,676 | $5.36M | $6.79M | - | $1.43M | 26.63% | +0.892% |
ABBV AbbVie Inc. | 2,532 | $407,105.01 | $722,645.46 | - | $315,540.45 | 77.51% | +0.707% |
ABEV Ambev S.A. | 88,689 | $181,445.16 | $289,569.58 | - | $108,124.42 | 59.59% | +0.153% |
ABNB Airbnb, Inc. | 3,257 | $446,633.32 | $567,108.84 | - | $120,475.52 | 26.97% | -0.092% |
ABT Abbott Laboratories | 2,399 | $217,685 | $251,151.31 | - | $33,466.31 | 15.37% | +0.01% |
ADI Analog Devices, Inc. | 751 | $239,734.83 | $305,675.77 | - | $65,940.94 | 27.51% | +0.761% |
ADP Automatic Data Processing Inc. | 2,423 | $563,442.41 | $694,141.04 | - | $130,698.63 | 23.2% | +0.291% |
AEP American Electric Power Company, Inc. | 1,819 | $204,968.45 | $230,612.82 | - | $25,644.37 | 12.51% | +2.003% |
AIG American International Group Inc. | 2,695 | $219,643.22 | $216,273.75 | - | -$3,369.47 | -1.53% | +1.428% |
AIQ Global X Artificial Intelligence & Technology ETF | 4,502 | $222,364 | $281,510.06 | - | $59,146.06 | 26.6% | -2.434% |
AJG Arthur J. Gallagher & Co. | 1,031 | $236,639 | $259,079.99 | - | $22,440.99 | 9.48% | +0.476% |
ALIT Alight Inc. | 19,204 | $10,754 | $180,805.66 | - | $170,051.66 | 1,581.29% | +2.115% |
AMAT Applied Materials, Inc. | 3,391 | $558,119.43 | $1.42M | - | $862,167.01 | 154.48% | -2.598% |
AMD Advanced Micro Devices, Inc. | 5,158 | $757,653.48 | $2.8M | - | $2.04M | 269.64% | -3.428% |
AMGN Amgen Inc. | 586 | $206,492.61 | $255,021.34 | - | $48,528.73 | 23.5% | +0.267% |
AMP Ameriprise Financial, Inc. | 2,045 | $791,734.1 | $1.02M | - | $232,994.95 | 29.43% | -0.296% |
AMZN Amazon.com Inc | 7,426 | $1.38M | $1.87M | - | $498,004.64 | 36.18% | -0.926% |
ANET Arista Networks, Inc. | 5,406 | $547,111.91 | $969,349.86 | - | $422,237.95 | 77.18% | -3.379% |
APH Amphenol Corporation | 13,192 | $229,620.4 | $1.06M | - | $832,599.44 | 362.6% | -1.19% |
AR Antero Resources Corporation | 131,863 | $4.65M | $5.03M | - | $376,525.09 | 8.1% | +4.597% |